Get the Stockscreener App
22.99
0.94%
0.1735
Caredx Inc stock is traded at $22.99, with a volume of 409.60K.
It is up +0.94% in the last 24 hours and up +7.13% over the past month.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
See More
Previous Close:
$22.82
Open:
$22.73
24h Volume:
409.60K
Relative Volume:
0.60
Market Cap:
$1.19B
Revenue:
$412.82M
Net Income/Loss:
$-8.19M
P/E Ratio:
-149.21
EPS:
-0.1541
Net Cash Flow:
$64.17M
1W Performance:
+6.49%
1M Performance:
+7.13%
6M Performance:
+34.07%
1Y Performance:
+35.57%
1-Day Range:
$21.95
$23.14
1-Week Range:
$21.33
$23.14
52-Week Range:
$10.96
$23.24
Caredx Inc Stock (CDNA) Company Profile
Name
Caredx Inc
Sector
Industry
Phone
415-287-2300
Address
8000 MARINA BLVD, BRISBANE, CA
Compare CDNA vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDNA
Caredx Inc
|
23.00 | 1.18B | 412.82M | -8.19M | 64.17M | -0.1541 |
TMO
Thermo Fisher Scientific Inc
|
493.17 | 183.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
180.35 | 129.29B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
569.00 | 44.45B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
136.53 | 38.25B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
376.77 | 37.66B | 3.77B | 449.25M | 240.68M | 7.8556 |
Caredx Inc Stock (CDNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-26-25 | Initiated | William Blair | Mkt Perform |
| Jan-15-25 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Aug-28-24 | Initiated | Wells Fargo | Underweight |
| Aug-19-24 | Upgrade | BTIG Research | Neutral → Buy |
| May-13-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-24 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-09-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| Aug-15-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-11-23 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-07-23 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-03-23 | Downgrade | Craig Hallum | Buy → Hold |
| Mar-03-23 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Jul-20-21 | Resumed | BTIG Research | Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-26-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-30-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-08-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-02-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-26-20 | Initiated | BTIG Research | Buy |
| Jun-19-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| May-09-19 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-15-19 | Initiated | Jefferies | Buy |
| Oct-23-18 | Resumed | Raymond James | Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Neutral |
| Nov-27-17 | Initiated | H.C. Wainwright | Buy |
| Jun-14-16 | Reiterated | Mizuho | Buy |
| Sep-29-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-25-15 | Initiated | Craig Hallum | Buy |
| Mar-18-15 | Reiterated | Mizuho | Buy |
View All
Caredx Inc Stock (CDNA) Latest News
U.S. Supreme Court rejects Natera, CareDx false-advertising dispute - Reuters
CareDx (CDNA) Supreme Court Appeal Denied, Lower Court Ruling St - GuruFocus
Justices Skip CareDx's Bid To Revive $45M False Ad Award - Law360
CAREDX INC (NASDAQ:CDNA) Shows Perfect Minervini Trend Template and High Growth Momentum Setup - ChartMill
The Technical Signals Behind (CDNA) That Institutions Follow - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF) and CareDx (CDNA) - The Globe and Mail
William Blair Maintains CareDx(CDNA.US) With Hold Rating - Moomoo
28% Of This CareDx Insider's Holdings Were Sold - Moomoo
CDNA Technical Analysis & Stock Price Forecast - Intellectia AI
CareDx to Participate in Upcoming June 2026 Investor Conferences - BioSpace
CareDx plans June talks at Jefferies and Goldman Sachs healthcare events - Stock Titan
CareDx to Participate in Upcoming Investor Conferences - The Joplin Globe
CareDx Earnings Call: Growth, Navaris Deal and Pivot - TipRanks
Precision Trading with Caredx Inc. (CDNA) Risk Zones - Stock Traders Daily
Insider Sell Alert: Arthur Torres Sells Shares of CareDx Inc (CD - GuruFocus
CareDx director Arthur Torres sells $214,675 in company stock By Investing.com - Investing.com Nigeria
CareDx director Arthur Torres sells $214,675 in company stock - Investing.com
CareDx (CDNA) director sells 10,570 shares in open-market trades - Stock Titan
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE's CareDx Inc(CDNA) Holding History - GuruFocus
ETFs Investing in CareDx, Inc. Stocks - TradingView
Rule 144 notice and recent sale by insider (CDNA) - Stock Titan
CareDx Lawsuit Resolution Refocuses Attention On Valuation And Growth Prospects - Sahm
[144] CareDx, Inc. SEC Filing - Stock Titan
CareDx expands HeartCare platform to transform post transplant care for heart recipients - Traders Union
How Investors Are Reacting To CareDx (CDNA) Profit Return, Higher 2026 Outlook And New Shelf Registration - Sahm
CareDx (CDNA) Successfully Resolves Legal Action - GuruFocus
Caredx announces dismissal of 2021 qui tam suit - marketscreener.com
CareDx(CDNA) Stock Options Chain | Quotes & News - Moomoo
CareDx Announces Dismissal of 2021 Qui Tam Suit - marketscreener.com
Earnings Preview: CareDx to Report Financial Results Post-market on April 28 - Moomoo
Technical Reactions to CDNA Trends in Macro Strategies - Stock Traders Daily
Insider Sell: Jeffrey Novack Sells 2,688 Shares of CareDx Inc (C - GuruFocus
CareDx (NASDAQ: CDNA) counsel's 2,688-share sale under 10b5-1 - Stock Titan
CareDx (CDNA) Q1 2026 Earnings Call Transcript - AOL.com
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The National Law Review
A Look At CareDx (CDNA) Valuation After Recent Share Price Momentum Cools - Yahoo Finance
CareDx (CDNA) General Counsel has 2,873 shares withheld to cover RSU taxes - Stock Titan
How Investors Are Reacting To CareDx (CDNA) Profitability Milestone And Higher 2026 Revenue Guidance - Sahm
CareDx (NASDAQ:CDNA) Upgraded to Strong-Buy at Wall Street Zen - MarketBeat
MSN Money - MSN
23 new CareDx hires receive 63,856 stock units under Nasdaq rule - Stock Titan
CareDx sharpens focus on core testing services - MSN
CareDx (CDNA) Q2 2025 Earnings Transcript - AOL.com
CareDx : 2025 Annual Report - marketscreener.com
CareDx : 2026 Proxy Statement - marketscreener.com
CDNA SEC FilingsCaredx 10-K, 10-Q, 8-K Forms - Stock Titan
Analysts Conflicted on These Healthcare Names: CareDx (CDNA), Biogen (BIIB) and Guardant Health (GH) - The Globe and Mail
H.C. Wainwright reiterates Neutral rating on CareDx stock By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Neutral rating on CareDx stock - Investing.com
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), Stryker (SYK) and CareDx (CDNA) - The Globe and Mail
CareDx Acquires Navaris and Divests Lab Products to Accelerate Growth - HarianBasis.co
Caredx Inc Stock (CDNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Caredx Inc Stock (CDNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| TORRES ARTHUR A | Director |
May 14 '26 |
Sale |
20.97 |
4,086 |
85,698 |
45,149 |
0.34%
0.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):